TY  - JOUR
AU  - Kreuz, W
AU  - Escuriola Ettingshausen, C
AU  - Vdovin, V
AU  - Zozulya, N
AU  - Plyushch, O
AU  - Svirin, P
AU  - Andreeva, T
AU  - Bubanská, E
AU  - Campos, M
AU  - Benedik-Dolničar, M
AU  - Jiménez-Yuste, V
AU  - Kitanovski, L
AU  - Klukowska, A
AU  - Momot, A
AU  - Osmulskaya, N
AU  - Prieto, M
AU  - Šalek, S Z
AU  - Velasco, F
AU  - Pavlova, A
AU  - Oldenburg, J
AU  - Knaub, S
AU  - Jansen, M
AU  - Belyanskaya, L
AU  - Walter, O
AU  - ObsITI study group
AU  - ObsITI committee
PY  - 2015
DO  - 10.1111/hae.12774
UR  - http://hdl.handle.net/10668/10016
T2  - Haemophilia : the official journal of the World Federation of Hemophilia
AB  - Development of neutralizing inhibitors against factor VIII (FVIII) is a major complication of haemophilia A treatment. The ongoing, international, open-label, uncontrolled, observational immune tolerance induction (ObsITI) study evaluates ITI, the...
LA  - en
KW  - Bonn protocol
KW  - factor VIII inhibitors
KW  - factor VIII/von Willebrand factor concentrate
KW  - haemophilia A
KW  - immune tolerance induction
KW  - poor prognosis for immune tolerance induction
KW  - Adolescent
KW  - Adult
KW  - Antibodies, Neutralizing
KW  - Child
KW  - Child, Preschool
KW  - Drug Combinations
KW  - Factor VIII
KW  - Female
KW  - Hemophilia A
KW  - Hemorrhage
KW  - Humans
KW  - Immune Tolerance
KW  - Infant
KW  - Male
KW  - Prognosis
KW  - Prospective Studies
KW  - Risk Factors
KW  - Safety
KW  - Young Adult
KW  - von Willebrand Factor
TI  - First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.
TY  - research article
VL  - 22
ER  -